176 related articles for article (PubMed ID: 36204243)
1. The STAGED-PKD 2-Stage Adaptive Study With a Patient Enrichment Strategy and Treatment Effect Modeling for Improved Study Design Efficiency in Patients With ADPKD.
Perrone RD; Hariri A; Minini P; Ahn C; Chapman AB; Horie S; Knebelmann B; Mrug M; Ong ACM; Pei YPC; Torres VE; Modur V; Gansevoort RT
Kidney Med; 2022 Oct; 4(10):100538. PubMed ID: 36204243
[TBL] [Abstract][Full Text] [Related]
2. Venglustat, a Novel Glucosylceramide Synthase Inhibitor, in Patients at Risk of Rapidly Progressing ADPKD: Primary Results of a Double-Blind, Placebo-Controlled, Phase 2/3 Randomized Clinical Trial.
Gansevoort RT; Hariri A; Minini P; Ahn C; Chapman AB; Horie S; Knebelmann B; Mrug M; Ong ACM; Pei YPC; Torres VE; Modur V; Antonshchuk I; Perrone RD
Am J Kidney Dis; 2023 May; 81(5):517-527.e1. PubMed ID: 36535535
[TBL] [Abstract][Full Text] [Related]
3. Prognostic enrichment design in clinical trials for autosomal dominant polycystic kidney disease: the HALT-PKD clinical trial.
Irazabal MV; Abebe KZ; Bae KT; Perrone RD; Chapman AB; Schrier RW; Yu AS; Braun WE; Steinman TI; Harris PC; Flessner MF; Torres VE;
Nephrol Dial Transplant; 2017 Nov; 32(11):1857-1865. PubMed ID: 27484667
[TBL] [Abstract][Full Text] [Related]
4. Metformin Therapy in Autosomal Dominant Polycystic Kidney Disease: A Feasibility Study.
Brosnahan GM; Wang W; Gitomer B; Struemph T; George D; You Z; Nowak KL; Klawitter J; Chonchol MB
Am J Kidney Dis; 2022 Apr; 79(4):518-526. PubMed ID: 34391872
[TBL] [Abstract][Full Text] [Related]
5. Octreotide-LAR in later-stage autosomal dominant polycystic kidney disease (ALADIN 2): A randomized, double-blind, placebo-controlled, multicenter trial.
Perico N; Ruggenenti P; Perna A; Caroli A; Trillini M; Sironi S; Pisani A; Riccio E; Imbriaco M; Dugo M; Morana G; Granata A; Figuera M; Gaspari F; Carrara F; Rubis N; Villa A; Gamba S; Prandini S; Cortinovis M; Remuzzi A; Remuzzi G;
PLoS Med; 2019 Apr; 16(4):e1002777. PubMed ID: 30951521
[TBL] [Abstract][Full Text] [Related]
6. Plasma metabolites and lipids associate with kidney function and kidney volume in hypertensive ADPKD patients early in the disease course.
Kim K; Trott JF; Gao G; Chapman A; Weiss RH
BMC Nephrol; 2019 Feb; 20(1):66. PubMed ID: 30803434
[TBL] [Abstract][Full Text] [Related]
7. Yinang formulation versus placebo granules as a treatment for chronic kidney disease stages III-IV in patients with autosomal dominant polycystic kidney disease: study protocol for a double-blind placebo-controlled randomized clinical trial.
Gan J; Wu Y; Gong X; Ma Y; Yu S; Gao J
Trials; 2019 Aug; 20(1):481. PubMed ID: 31391092
[TBL] [Abstract][Full Text] [Related]
8. Tolvaptan and Kidney Function Decline in Older Individuals With Autosomal Dominant Polycystic Kidney Disease: A Pooled Analysis of Randomized Clinical Trials and Observational Studies.
Chebib FT; Zhou X; Garbinsky D; Davenport E; Nunna S; Oberdhan D; Fernandes A
Kidney Med; 2023 Jun; 5(6):100639. PubMed ID: 37250503
[TBL] [Abstract][Full Text] [Related]
9. Factors predicting decline in renal function and kidney volume growth in autosomal dominant polycystic kidney disease: a prospective cohort study (Japanese Polycystic Kidney Disease registry: J-PKD).
Uchiyama K; Mochizuki T; Shimada Y; Nishio S; Kataoka H; Mitobe M; Tsuchiya K; Hanaoka K; Ubara Y; Suwabe T; Sekine A; Nutahara K; Tsuruya K; Ishimura E; Nakatani S; Sofue T; Tanaka S; Narita I; Maruyama S; Horie S; Muto S
Clin Exp Nephrol; 2021 Sep; 25(9):970-980. PubMed ID: 33928479
[TBL] [Abstract][Full Text] [Related]
10. Rationale and design of the DIPAK 1 study: a randomized controlled clinical trial assessing the efficacy of lanreotide to Halt disease progression in autosomal dominant polycystic kidney disease.
Meijer E; Drenth JP; d'Agnolo H; Casteleijn NF; de Fijter JW; Gevers TJ; Kappert P; Peters DJ; Salih M; Soonawala D; Spithoven EM; Torres VE; Visser FW; Wetzels JF; Zietse R; Gansevoort RT;
Am J Kidney Dis; 2014 Mar; 63(3):446-55. PubMed ID: 24342522
[TBL] [Abstract][Full Text] [Related]
11. Rationale and Design of a Clinical Trial Investigating Tolvaptan Safety and Efficacy in Autosomal Dominant Polycystic Kidney Disease.
Torres VE; Devuyst O; Chapman AB; Gansevoort RT; Perrone RD; Ouyang J; Blais JD; Czerwiec FS; Sergeyeva O;
Am J Nephrol; 2017; 45(3):257-266. PubMed ID: 28166521
[TBL] [Abstract][Full Text] [Related]
12. Baseline Characteristics and Patient-Reported Outcomes of ADPKD Patients in the Multicenter TAME-PKD Clinical Trial.
Seliger SL; Watnick T; Althouse AD; Perrone RD; Abebe KZ; Hallows KR; Miskulin DC; Bae KT
Kidney360; 2020 Dec; 1(12):1363-1372. PubMed ID: 33768205
[TBL] [Abstract][Full Text] [Related]
13. Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study.
Torres VE; Meijer E; Bae KT; Chapman AB; Devuyst O; Gansevoort RT; Grantham JJ; Higashihara E; Perrone RD; Krasa HB; Ouyang JJ; Czerwiec FS
Am J Kidney Dis; 2011 May; 57(5):692-9. PubMed ID: 21333426
[TBL] [Abstract][Full Text] [Related]
14. Hemorrhagic Cysts and Other MR Biomarkers for Predicting Renal Dysfunction Progression in Autosomal Dominant Polycystic Kidney Disease.
Riyahi S; Dev H; Blumenfeld JD; Rennert H; Yin X; Attari H; Barash I; Chicos I; Bobb W; Donahue S; Prince MR
J Magn Reson Imaging; 2021 Feb; 53(2):564-576. PubMed ID: 32969110
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Enrichment Design in Clinical Trials for Autosomal Dominant Polycystic Kidney Disease: The TEMPO 3:4 Clinical Trial.
Irazabal MV; Blais JD; Perrone RD; Gansevoort RT; Chapman AB; Devuyst O; Higashihara E; Harris PC; Zhou W; Ouyang J; Czerwiec FS; Torres VE
Kidney Int Rep; 2016 Nov; 1(4):213-220. PubMed ID: 29142926
[TBL] [Abstract][Full Text] [Related]
16. RESET-PKD: a pilot trial on short-term ketogenic interventions in autosomal dominant polycystic kidney disease.
Oehm S; Steinke K; Schmidt J; Arjune S; Todorova P; Heinrich Lindemann C; Wöstmann F; Meyer F; Siedek F; Weimbs T; Müller RU; Grundmann F
Nephrol Dial Transplant; 2023 Jun; 38(7):1623-1635. PubMed ID: 36423335
[TBL] [Abstract][Full Text] [Related]
17. Health-related quality of life in patients with autosomal dominant polycystic kidney disease and CKD stages 1-4: a cross-sectional study.
Miskulin DC; Abebe KZ; Chapman AB; Perrone RD; Steinman TI; Torres VE; Bae KT; Braun W; Winklhofer FT; Hogan MC; Rahbari-Oskoui F; Moore CG; Flessner MF; Schrier RW;
Am J Kidney Dis; 2014 Feb; 63(2):214-26. PubMed ID: 24183837
[TBL] [Abstract][Full Text] [Related]
18. Randomised controlled trial to determine the efficacy and safety of prescribed water intake to prevent kidney failure due to autosomal dominant polycystic kidney disease (PREVENT-ADPKD).
Wong ATY; Mannix C; Grantham JJ; Allman-Farinelli M; Badve SV; Boudville N; Byth K; Chan J; Coulshed S; Edwards ME; Erickson BJ; Fernando M; Foster S; Haloob I; Harris DCH; Hawley CM; Hill J; Howard K; Howell M; Jiang SH; Johnson DW; Kline TL; Kumar K; Lee VW; Lonergan M; Mai J; McCloud P; Peduto A; Rangan A; Roger SD; Sud K; Torres V; Vilayur E; Rangan GK
BMJ Open; 2018 Jan; 8(1):e018794. PubMed ID: 29358433
[TBL] [Abstract][Full Text] [Related]
19. Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials.
Irazabal MV; Rangel LJ; Bergstralh EJ; Osborn SL; Harmon AJ; Sundsbak JL; Bae KT; Chapman AB; Grantham JJ; Mrug M; Hogan MC; El-Zoghby ZM; Harris PC; Erickson BJ; King BF; Torres VE;
J Am Soc Nephrol; 2015 Jan; 26(1):160-72. PubMed ID: 24904092
[TBL] [Abstract][Full Text] [Related]
20. Visceral Adiposity and Progression of ADPKD: A Cohort Study of Patients From the TEMPO 3:4 Trial.
Nowak KL; Moretti F; Bussola N; Steele CN; Gregory AV; Kline TL; Ramanathan S; Trapletti G; Furlanello C; McCormick L; Chonchol M
Am J Kidney Dis; 2024 Apr; ():. PubMed ID: 38608748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
